{"entity":{"id":"gq11-inhibitor-payloads","kind":"term","name":"Gq/11 inhibitor payloads","aka":["SDZ475","DYP688 payload","GNAQ GNA11 inhibitor conjugates"],"tldr":"These payloads block a cell signal that drives some melanomas. An antibody carries the inhibitor into cells bearing a melanoma-associated surface protein.","summary":"DYP688 targets the surface protein PMEL and delivers the Gq/11 inhibitor SDZ475. A published phase 1 study in metastatic uveal melanoma and other GNAQ/GNA11-mutant melanomas reported human safety and preliminary activity. This is direct pathway inhibition rather than a conventional tubulin or DNA-damaging payload. The study was an early dose-escalation trial, so it does not establish a comparative survival benefit or approval.","asOf":"2026-11-08","links":[{"label":"DYP688 phase 1 clinical study (2026)","url":"https://doi.org/10.1038/s41591-026-04518-z"},{"label":"ClinicalTrials.gov: NCT05415072","url":"https://clinicaltrials.gov/study/NCT05415072"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["adc"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["payload"],"trials":["nct05415072"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"ADC chemistry"},"route":"/terms/gq11-inhibitor-payloads/","neighbours":{"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"term":[{"id":"next-generation-adc-payloads","kind":"term","name":"Next-generation antibody-conjugate payloads","route":"/terms/next-generation-adc-payloads/"},{"id":"payload","kind":"term","name":"Payload (ADC)","route":"/terms/payload/"}],"trial":[{"id":"nct05415072","kind":"trial","name":"A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas","route":"/trials/nct05415072/"}]}}